Evercore ISI upgraded shares of TESARO (NASDAQ:TSRO) from an in-line rating to an outperform rating in a research report report published on Thursday morning, Marketbeat reports. They currently have $88.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts have also commented on the stock. BidaskClub lowered shares of TESARO from a sell rating to a strong sell rating in a research report on Saturday, February 10th. Piper Jaffray Companies reaffirmed a hold rating and set a $65.00 price objective on shares of TESARO in a research report on Thursday, January 18th. Credit Suisse Group reaffirmed an outperform rating and set a $150.00 price objective (down previously from $190.00) on shares of TESARO in a research report on Thursday, January 18th. Morgan Stanley cut their price objective on shares of TESARO from $165.00 to $156.00 and set an overweight rating for the company in a research report on Tuesday, January 16th. Finally, HC Wainwright reaffirmed a buy rating and set a $158.00 price objective on shares of TESARO in a research report on Friday, January 12th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $148.60.
TESARO (NASDAQ:TSRO) opened at $60.89 on Thursday. The firm has a market cap of $3,372.22, a price-to-earnings ratio of -7.21 and a beta of 1.25. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO has a 52-week low of $55.02 and a 52-week high of $190.74.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 40.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Exane Derivatives raised its position in TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,123 shares in the last quarter. Toronto Dominion Bank raised its position in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares in the last quarter. Bourgeon Capital Management LLC acquired a new position in TESARO in the fourth quarter worth about $211,000. Fox Run Management L.L.C. acquired a new position in TESARO in the fourth quarter worth about $218,000. Finally, Commonwealth Equity Services Inc acquired a new position in TESARO in the third quarter worth about $222,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.